COSTS ASSOCIATED TO THE TREATMENT OF DIFFERENT STAGES OF MEXICAN BREAST CANCER PATIENTS
1Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico, 2Instituto Mexicano del Seguro Social, Delegación Cuauhtémoc, Distrito Federal, Mexico, 3Pfizer S.A. de C.V., Mexico City, Mexico, 4Secretaría de Salud. Hospital Infantil de México, México D.F., Mexico, 5Secretaría de Salud. Hospital Infantil de México, México D.F., Mexico, 6Instituto Mexicano de Seguro Social. UMAE HE CMNO, Guadalajara, Jalisco, Mexico
OBJECTIVES: To describe costs associated to the treatment of different stages of breast cancer patients at the Social Security Mexican Institute (IMSS) from the health care payer’s perspective.

METHODS: A cost study was elaborated. Resource use and cost data were obtained from hospital (second and tertiary levels) records of 313 treated patients during July 2008 to February 2009 using the following inclusion criteria: women older than 16 years with breast cancer histological diagnosis who accepted to be included in the protocol through informed consent. Although, patients excluded were those who showed a second malignant neoplasm or incomplete information. We calculate mean, median, 95% confidence interval (95% CI) for each clinical stage and statistical differences were estimated through ANOVA tests, p value <0.05 was considered significant to show differences. RESULTS: The median total cost per patient was found in US $4161.38 (95% CI, US $426.19–US $4156.63); all chemotherapy treatment resulted in US $2702.03, (95% CI, US $1456.36-US $5503.49) and median costs per patient with radiotherapy resulted in US $1260.78 (95% CI, US $421.34-US $1260.78). The mean cost per patient in each clinical stage with chemotherapy was: I: US $1830.80 (95% CI, US $666.21–US $2975.39); II: US $1543.41 (95% CI, US $370.19-US $4716.62); III: US $4079.77 (95% CI, US $2739.86-US $5419.68); IV: US $9407.21 (95% CI, US $672.11-US $9142.31) and in each stage with radiotherapy was: I: US $1596.66 (95% CI, US $336.94-US $7140.40); p < 0.401. CONCLUSIONS: The results showed that at the IMSS, it is more expensive the treatment of breast cancer patients in clinical stage III; however, the less expensive treatments resulted for patients in clinical stage I. In addition, the treatment of non classified patients were the second most expensive according to our results.

COSTS ASSOCIATED TO THE TREATMENT OF DIFFERENT STAGES OF MEXICAN PATIENTS WITH COLORECTAL CANCER
1Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico, 2Instituto Mexicano del Seguro Social, Delegación Cuauhtémoc, Distrito Federal, Mexico, 3Pfizer S.A. de C.V., Mexico City, Mexico, 4Instituto Mexicano del Seguro Social. UMAE HE CMNO, Guadalajara, Jalisco, Mexico, 5Secretaría de Salud. Hospital Infantil de México, México D.F., Mexico, 6Instituto Mexicano de Seguro Social. UMAE HE CMNO, Guadalajara, Jalisco, Mexico
OBJECTIVES: To describe costs associated to the treatment of different stages of colorectal cancer at the Social Security Mexican Institute (IMSS) from the health care payer’s perspective. METHODOLOGY: A cost study was made. Resource use and cost data were obtained from hospital (second and tertiary levels) records of 115 treated patients from July 2008 to February 2009 using the following inclusion criteria: patients older than 16 years with colorectal cancer histological diagnosis who accepted to be included in the protocol through informed consent. Although, patients excluded were those who showed a second malignant neoplasm or incomplete information. We calculated mean, standard deviation (SD), median, 25 percent and 75 percent for each clinical stage and statistical differences were estimated through ANOVA tests, p value <0.05 was considered significant to show differences. RESULTS: The median total cost per patient was US $3,263.52 (US $2,111.29 to US $4,881.14), the mean cost per patient was US $402.40 (SD: US $57.20). The mean cost per patient in each clinical stage to chemotherapy was US $1366.99 (SD: US $2258.67), II: US $3843.45 (SD: US $1381.09), III: US $5254.36 (SD: US $922.43), IV: US $2500.40 (SD: US $1232.60) and the non classified: US $2653.25 (SD: US $1316.95) p = 0.511. CONCLUSIONS: The results show that in México, in more expensive the treatment to patients with non-hodgkin lymphoma in clinical stage III.